98%
921
2 minutes
20
It is clear that interdisciplinary communication and collaboration have the potential to mitigate healthcare-associated harm, yet there is limited research on how communication through documentation in the patient record can support collaborative decision making. Understanding what information is needed to support collaborative decision making is necessary to design electronic health information systems that facilitate effective communication and, ultimately, safe care. To explore this issue, we focused on information needs related to central venous catheter management and the prevention of central line-associated blood stream infections. Semistructured interviews were conducted with nurses working in an intensive care unit. Interview transcripts were analyzed using inductive thematic analysis. Three themes were identified: (1) challenges managing documentation in multiple places in the absence of formal documentation processes for central venous catheter management; (2) lack of standardized decision-making processes for managing central venous catheters; and (3) oral communication holds it together. Our findings provide a foundation for the development of EHR functional requirements that enhance communication regarding the management of central venous catheters and facilitate the prompt removal of unnecessary lines.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446958 | PMC |
http://dx.doi.org/10.1097/CIN.0000000000000683 | DOI Listing |
Infect Drug Resist
September 2025
Department of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Objective: To investigate the clinical efficacy and safety of intravenous omadacycline compared to intravenous tigecycline in patients with severe pneumonia caused by carbapenem-resistant gram-negative bacilli (CRGNB), and to explore the factors influencing 28-day all-cause mortality.
Methods: Our retrospective analysis was conducted on adult patients with CRGNB-associated severe pneumonia who received intravenous omadacycline or tigecycline for at least 72 hours in the intensive care unit (ICU) between April 1, 2023, and March 31, 2025. The primary outcome was 28-day all-cause mortality, while secondary endpoints included clinical efficacy and microbiological clearance rates.
Curr Med Imaging
May 2025
Department of Radiology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Background: Predicting the recurrence risk of NMIBC after TURBT is crucial for individualized clinical treatment.
Objective: The objective of this study is to evaluate the ability of radiomic feature analysis of intratumoral and peritumoral regions based on computed tomography (CT) imaging to predict recurrence in non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder tumor (TURBT).
Methods: A total of 233 patients with NMIBC who underwent TURBT were retrospectively analyzed.
Arterial thrombosis is a multifaceted process characterized by platelet aggregation and fibrin deposition, leading to the occlusion of blood vessels. It plays a central role in cardiovascular conditions such as myocardial infarction and ischemic stroke. Gaining insight into the mechanisms underlying arterial thrombosis is essential for developing effective treatments aimed at preventing thrombotic events and reducing associated health burdens.
View Article and Find Full Text PDFKhirurgiia (Mosk)
September 2025
Mandryka Central Military Clinical Hospital, Moscow, Russia.
Widespread fragmentation shells in combat operations with frequent multiple damage to organs and systems force to use all available diagnostic methods for treating severe injuries including lesion of great vessels of extremities. One of the consequences of these lesions is arteriovenous fistula (AVF). The last one may be asymptomatic at first.
View Article and Find Full Text PDFN Engl J Med
September 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.
Methods: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib.